scholarly journals Anaplastic Lymphoma Kinase-Positive Primary Lung Adenocarcinoma Presenting With Pericardial Effusion and Tamponade in a COVID-19 Patient: A Case Report

Cureus ◽  
2021 ◽  
Author(s):  
Ateeb Ur Rahman ◽  
Olufunmilayo Folaranmi ◽  
Vernon Chan ◽  
Amna Chaudary
Keyword(s):  
Case Report ◽  
Pericardial Effusion ◽  
Lung Adenocarcinoma ◽  
Anaplastic Lymphoma Kinase ◽  
Anaplastic Lymphoma ◽  
Primary Lung Adenocarcinoma

Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report

Lung Cancer ◽  
2016 ◽  
Vol 99 ◽  
pp. 66-68 ◽  
Author(s):  
Masayuki Shirasawa ◽  
Masaru Kubota ◽  
Shinya Harada ◽  
Hideyuki Niwa ◽  
Seiichiro Kusuhara ◽  
...  
Keyword(s):  
Case Report ◽  
Lung Adenocarcinoma ◽  
Skin Rash ◽  
Anaplastic Lymphoma Kinase ◽  
Anaplastic Lymphoma ◽  
Oral Desensitization

scholarly journals Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Wen Dong ◽  
Pengfei Lei ◽  
Xin Liu ◽  
Qin Li ◽  
Xiangyang Cheng
Keyword(s):  
Cell Death ◽  
Case Report ◽  
Programmed Cell Death ◽  
Tyrosine Kinase ◽  
Lung Adenocarcinoma ◽  
Anaplastic Lymphoma Kinase ◽  
Gene Rearrangement ◽  
Multiple Gene ◽  
Anaplastic Lymphoma ◽  
Programmed Cell Death 1

Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.

scholarly journals Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report

2013 ◽  
Vol 2 (1) ◽  
pp. 121-123 ◽  
Author(s):  
OSAMU TAKAKUWA ◽  
TETSUYA OGURI ◽  
MIDORI YOKOYAMA ◽  
HISATOSHI HIJIKATA ◽  
TAKEHIRO UEMURA ◽  
...  
Keyword(s):  
Case Report ◽  
Lung Adenocarcinoma ◽  
Anaplastic Lymphoma Kinase ◽  
Anaplastic Lymphoma ◽  
Anaplastic Lymphoma Kinase Rearrangement
Sign in / Sign up

Export Citation Format

Share Document